MedPath

Nitroglycerin

Generic Name
Nitroglycerin
Brand Names
Gonitro, Minitran, Mylan-nitro, Nitro-bid, Nitro-dur, Nitroject, Nitrolingual, Nitromist, Nitrostat, Rectiv, Trinipatch
Drug Type
Small Molecule
Chemical Formula
C3H5N3O9
CAS Number
55-63-0
Unique Ingredient Identifier
G59M7S0WS3
Background

Nitroglycerin, also known as glyceryl trinitrate, is an organic nitrate and a vasodilating agent that was first discovered in 1847. Originally used to dynamite, its antianginal effects were identified in the late 1860s after it produced headaches in factory workers while workers with angina pectoris or heart failure experienced relief from chest pain. Its use as a treatment for angina dates back to 1879 and is still used to treat and prevent angina. Nitroglycerin causes vasodilation in both arteries and veins.

Nitroglycerin is used in a variety of different conditions, including angina pectoris due to coronary artery disease, peri-operative hypertension, congestive heart failure, and chronic anal fissure. It is also used to induce intraoperative hypotension.

Indication

Sublingual nitroglycerin is indicated for the acute relief of an attack or acute prophylaxis of angina pectoris due to coronary artery disease. Transdermal nitroglycerin is indicated for the prevention of angina pectoris due to coronary artery disease.

Intravenous nitroglycerin is indicated for the treatment of peri-operative hypertension; for control of congestive heart failure in the setting of acute myocardial infarction; for treatment of angina pectoris in patients who have not responded to sublingual nitroglycerin and beta (β)-blockers; and for induction of intraoperative hypotension.

Topical nitroglycerin ointment is used to treat moderate to severe pain associated with chronic anal fissure.

Associated Conditions
Angina Attacks, Angina Pectoris, Congestive Heart Failure (CHF), Perioperative Hypertension, Moderate to severe pain

Effect of Nitric Oxide Donor on Endothelial Progenitor Cells in Patients With Coronary Artery Disease

Phase 2
Completed
Conditions
Coronary Artery Disease
First Posted Date
2004-08-27
Last Posted Date
2008-03-04
Lead Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Target Recruit Count
30
Registration Number
NCT00090558
Locations
🇺🇸

National Heart, Lung and Blood Institute (NHLBI), Bethesda, Maryland, United States

Nitroglycerin Ointment for Preventing Bone Loss in Postmenopausal Women

Phase 3
Completed
Conditions
Osteoporosis
Osteopenia
First Posted Date
2002-08-14
Last Posted Date
2009-02-02
Lead Sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Target Recruit Count
200
Registration Number
NCT00043719
Locations
🇺🇸

UMDNJ-Robert Wood Johnson Medical School, Department of Medicine, Division of Endocrinology, New Brunswick, New Jersey, United States

Effects of Nitric Oxide and Nitroglycerin in Patients With Sickle Cell Anemia

Phase 2
Completed
Conditions
Chest Pain
Sickle Cell Anemia
First Posted Date
1999-11-04
Last Posted Date
2008-03-04
Lead Sponsor
National Institutes of Health Clinical Center (CC)
Target Recruit Count
58
Registration Number
NCT00001716
Locations
🇺🇸

Warren G. Magnuson Clinical Center (CC), Bethesda, Maryland, United States

Randomized Clinical Trial of Non-Surgical Reperfusion of the Coronary Arteries

Phase 3
Completed
Conditions
Cardiovascular Diseases
Coronary Disease
Myocardial Ischemia
Heart Diseases
Myocardial Infarction
First Posted Date
1999-10-28
Last Posted Date
2013-11-26
Lead Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Registration Number
NCT00000503
© Copyright 2025. All Rights Reserved by MedPath